Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles J Ryan

Showing results (1-10 of 222) with videos related to

Pageof 23
Sort By:
Urologic Oncology|June 9, 2016
Targeting the Androgen Receptor: Remaining questions and future directionsCharles J Ryan
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
Abiraterone: current and future use in prostate cancerCharles J Ryan
Hematology/Oncology Clinics of North America|July 25, 2006
Secondary hormonal manipulations in prostate cancerCharles J Ryan
Urologic Oncology|July 25, 2016
Utility of novel androgen receptor therapies in the real world: A nuanced approachMallika Dhawan, Charles J Ryan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?"Charles J Ryan, Mario Eisenberger
Cancer|September 20, 2014
Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesWon Kim, Charles J Ryan
Oncology (Williston Park, N.Y.)|July 10, 2014
Friend or foe: the bifunctional role of steroid hormones in prostate cancerWon Kim, Charles J Ryan
Current Treatment Options in Oncology|April 28, 2012
Androgen receptor directed therapies in castration-resistant metastatic prostate cancerWon Kim, Charles J Ryan
Endocrine-Related Cancer|April 18, 2020
Androgen hazards with COVID-19Nima Sharifi, Charles J Ryan
Journal of Comparative Effectiveness Research|December 23, 2015
Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studiesWon Kim, Charles J Ryan
Pageof 23

Showing results (1-10 of 222) with videos related to

Sort By:
Pageof 23
Urologic Oncology|June 9, 2016
Targeting the Androgen Receptor: Remaining questions and future directionsCharles J Ryan
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
Abiraterone: current and future use in prostate cancerCharles J Ryan
Hematology/Oncology Clinics of North America|July 25, 2006
Secondary hormonal manipulations in prostate cancerCharles J Ryan
Urologic Oncology|July 25, 2016
Utility of novel androgen receptor therapies in the real world: A nuanced approachMallika Dhawan, Charles J Ryan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?"Charles J Ryan, Mario Eisenberger
Cancer|September 20, 2014
Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesWon Kim, Charles J Ryan
Oncology (Williston Park, N.Y.)|July 10, 2014
Friend or foe: the bifunctional role of steroid hormones in prostate cancerWon Kim, Charles J Ryan
Current Treatment Options in Oncology|April 28, 2012
Androgen receptor directed therapies in castration-resistant metastatic prostate cancerWon Kim, Charles J Ryan
Endocrine-Related Cancer|April 18, 2020
Androgen hazards with COVID-19Nima Sharifi, Charles J Ryan
Journal of Comparative Effectiveness Research|December 23, 2015
Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studiesWon Kim, Charles J Ryan
Pageof 23